Literature DB >> 33652258

Tumor-related stress regulates functional plasticity of MDSCs.

Jessica K Mandula1, Paulo C Rodriguez2.   

Abstract

Myeloid-derived suppressor cells (MDSCs) impair protective anti-tumor immunity and remain major obstacles that stymie the effectiveness of promising cancer therapies. Diverse tumor-derived stressors galvanize the differentiation, intra-tumoral expansion, and immunomodulatory function of MDSCs. These tumor-associated 'axes of stress' underwrite the immunosuppressive programming of MDSCs in cancer and contribute to the phenotypic/functional heterogeneity that characterize tumor-MDSCs. This review discusses various tumor-associated axes of stress that direct MDSC development, accumulation, and immunosuppressive function, as well as current strategies aimed at overcoming the detrimental impact of MDSCs in cancer. To better understand the constellation of signals directing MDSC biology, we herein summarize the pivotal roles, signaling mediators, and effects of reactive oxygen/nitrogen species-related stress, chronic inflammatory stress, hypoxia-linked stress, endoplasmic reticulum stress, metabolic stress, and therapy-associated stress on MDSCs. Although therapeutic targeting of these processes remains mostly pre-clinical, intercepting signaling through the axes of stress could overcome MDSC-related immune suppression in tumor-bearing hosts.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; ER stress; Immunotherapy; MDSC

Mesh:

Substances:

Year:  2021        PMID: 33652258      PMCID: PMC8026602          DOI: 10.1016/j.cellimm.2021.104312

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  186 in total

1.  The terminology issue for myeloid-derived suppressor cells.

Authors:  Dmitry I Gabrilovich; Vincenzo Bronte; Shu-Hsia Chen; Mario P Colombo; Augusto Ochoa; Suzanne Ostrand-Rosenberg; Hans Schreiber
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  Early-phase Treatment by Low-dose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation.

Authors:  Dai Otsubo; Kimihiro Yamashita; Mitsugu Fujita; Masayasu Nishi; Yutaka Kimura; Hiroshi Hasegawa; Satoshi Suzuki; Yoshihiro Kakeji
Journal:  Anticancer Res       Date:  2015-08       Impact factor: 2.480

3.  Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo.

Authors:  Brian R Rosborough; Antonino Castellaneta; Sudha Natarajan; Angus W Thomson; Heth R Turnquist
Journal:  J Leukoc Biol       Date:  2011-10-25       Impact factor: 4.962

4.  The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.

Authors:  Eslam Mohamed; Rosa A Sierra; Jimena Trillo-Tinoco; Yu Cao; Patrick Innamarato; Kyle K Payne; Alvaro de Mingo Pulido; Jessica Mandula; Shuzhong Zhang; Paul Thevenot; Subir Biswas; Sarah K Abdalla; Tara Lee Costich; Kay Hänggi; Carmen M Anadon; Elsa R Flores; Eric B Haura; Shikhar Mehrotra; Shari Pilon-Thomas; Brian Ruffell; David H Munn; Juan R Cubillos-Ruiz; Jose R Conejo-Garcia; Paulo C Rodriguez
Journal:  Immunity       Date:  2020-04-14       Impact factor: 31.745

5.  Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response.

Authors:  Zheng Sun; Zheping Huang; Donna D Zhang
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

6.  Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.

Authors:  Scott J Antonia; Noweeda Mirza; Ingo Fricke; Alberto Chiappori; Patricia Thompson; Nicholas Williams; Gerold Bepler; George Simon; William Janssen; Ji-Hyun Lee; Kerstin Menander; Sunil Chada; Dmitry I Gabrilovich
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

Review 7.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

8.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

Review 9.  Tumor refractoriness to anti-VEGF therapy.

Authors:  Domenico Ribatti
Journal:  Oncotarget       Date:  2016-07-19

Review 10.  Sunitinib: the antiangiogenic effects and beyond.

Authors:  Zhonglin Hao; Ibrahim Sadek
Journal:  Onco Targets Ther       Date:  2016-09-08       Impact factor: 4.147

View more
  1 in total

Review 1.  Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.

Authors:  Filippos Koinis; Anastasia Xagara; Evangelia Chantzara; Vassiliki Leontopoulou; Chrissovalantis Aidarinis; Athanasios Kotsakis
Journal:  Cells       Date:  2021-12-22       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.